PSPA
MCID: PTT048
MIFTS: 64

Pituitary Adenoma, Prolactin-Secreting (PSPA)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pituitary Adenoma, Prolactin-Secreting

MalaCards integrated aliases for Pituitary Adenoma, Prolactin-Secreting:

Name: Pituitary Adenoma, Prolactin-Secreting 57 12 13
Prolactinoma 12 20 58 72 54 44 15 70
Prolactin-Producing Pituitary Gland Adenoma 20 29 6 17
Prolactin-Secreting Pituitary Adenoma 20 58 72
Prl-Secreting Pituitary Adenoma 20 58
Pituitary Lactotrophic Adenoma 20 58
Lactotroph Adenoma 20 58
Prloma 20 58
Prolactinoma of Pituitary Gland 12
Prolactinoma, Familial 57
Familial Prolactinoma 12
Pspa 72

Characteristics:

Orphanet epidemiological data:

58
prolactinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
familial tendency independent of association with men-1


Classifications:

Orphanet: 58  
Rare infertility disorders
Rare endocrine diseases


Summaries for Pituitary Adenoma, Prolactin-Secreting

GARD : 20 Prolactinoma is a tumor of the pituitary gland that causes increased levels of the hormone prolactin. This hormone normally stimulates breast development and milk production in women. Prolactinoma can affect men or women. In women, the symptoms may include unusual milk production (galactorrhea) when not pregnant or nursing and having no menstrual cycles ( amenorrhea ). In men, the most common symptoms are decreased sex drive and infertility. Most prolactinomas occur by chance (sporadically) in people with no family history. In a small number of cases, prolactinoma may be caused by a genetic condition such as multiple endocrine neoplasia type 1 (MEN1) or familial isolated pituitary adenoma. Treatment for prolactinoma usually involves taking oral medications known as dopamine agonists. These medications can reduce prolactin levels and shrink the tumor. In more severe cases, radiation therapy or surgery may be needed.

MalaCards based summary : Pituitary Adenoma, Prolactin-Secreting, also known as prolactinoma, is related to prolactin producing pituitary tumor and pituitary adenoma 1, multiple types. An important gene associated with Pituitary Adenoma, Prolactin-Secreting is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Quinagolide and Cabergoline have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and bone, and related phenotypes are impotence and galactorrhea

OMIM® : 57 Prolactin-secreting pituitary adenoma, or prolactinoma, is the most common type of hormonally active pituitary adenoma. These tumors can also be seen as a feature of multiple endocrine neoplasia type I (MEN1; 131100). See also 102200 for a discussion of familial isolated pituitary adenoma (FIPA) and acromegaly due to a growth hormone (GH; 139250)-secreting pituitary adenoma, which are also caused by mutation in the AIP gene. Schlechte (2003) discussed prolactinoma in general terms as a clinical, diagnostic, and therapeutic problem. (600634) (Updated 20-May-2021)

UniProtKB/Swiss-Prot : 72 Prolactin-secreting pituitary adenoma: Most common type of hormonally active pituitary adenoma.

Related Diseases for Pituitary Adenoma, Prolactin-Secreting

Diseases related to Pituitary Adenoma, Prolactin-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.1 SSTR5 PRL POMC DRD2
2 pituitary adenoma 1, multiple types 31.9 SST PRL MEN1 IGF1 GH1 AIP
3 hyperprolactinemia 31.5 TRH SST PRL POMC IGF1 GH1
4 galactorrhea 31.5 PRL IGF1 DRD2
5 amenorrhea 31.3 TRH PRL POMC IGF1
6 pituitary tumors 31.2 SSTR5 SST PTTG1 PRL POMC MEN1
7 multiple endocrine neoplasia 31.1 SST PRKAR1A POMC MEN1 AIP
8 adenoma 31.0 TRH SSTR5 SSTR2 SST PRL PRKAR1A
9 diabetes insipidus 31.0 PRL POMC GH1
10 multiple endocrine neoplasia, type i 30.9 SST PRL PRKAR1A POMC MEN1 AIP
11 gigantism 30.9 PRL GH1 AIP
12 pituitary apoplexy 30.9 SST PRL POMC MEN1 IGF1 GH1
13 hypopituitarism 30.9 TRH PRL POU1F1 POMC IGF1 GH1
14 empty sella syndrome 30.8 TRH PRL POMC IGF1 GH1
15 intracranial hypertension, idiopathic 30.8 SSTR1 POMC IGF1
16 sexual disorder 30.8 PRL POMC IGF1
17 chromophobe adenoma 30.8 TRH PRL POMC GH1
18 meningioma, familial 30.7 SSTR5 SSTR2 SST PRKAR1A MEN1
19 hypothyroidism 30.7 TRH SST PRL POU1F1 POMC IGF1
20 pituitary carcinoma 30.6 SSTR2 SST PRL POMC MEN1
21 familial isolated pituitary adenoma 30.6 MEN1 LRP2 CDH23 AIP
22 parathyroid adenoma 30.5 PRKAR1A MEN1 IGF1
23 pituitary adenoma 30.5 TRH SSTR5 SSTR3 SSTR2 SST PTTG1
24 insulinoma 30.5 SSTR5 SSTR2 SST MEN1
25 gangliocytoma 30.5 PRL POMC
26 lactocele 30.5 TRH PRL
27 primary hyperparathyroidism 30.5 PRL PRKAR1A POMC MEN1 LRP2 IGF1
28 craniopharyngioma 30.4 TRH PTTG1 PRL POU1F1 IGF1 GH1
29 acromegaly 30.4 TRH SSTR5 SSTR2 SSTR1 SST PRL
30 hypoglycemia 30.3 SST PRL POMC IGF1 GH1
31 hyperandrogenism 30.3 PRL POMC IGF1
32 goiter 30.3 TRH SST PRL IGF1
33 insulin-like growth factor i 30.3 SST PRL LRP2 IGF1 GH1
34 lymphocytic hypophysitis 30.2 POMC GH1
35 non-functioning pituitary adenoma 30.2 SST GH1
36 abducens nerve disease 30.2 PRL POMC
37 carcinoid syndrome 30.2 SST MEN1 IGF1
38 diabetes insipidus, neurohypophyseal 30.2 TRH PRL POMC
39 gastrinoma 30.2 SSTR5 SSTR2 SSTR1 SST POMC MEN1
40 adrenal cortical adenoma 30.2 PRKAR1A POMC MEN1
41 hyperthyroidism 30.1 TRH SST PRL POMC IGF1 GH1
42 thyroid gland medullary carcinoma 30.1 SSTR2 SST POMC MEN1
43 adrenal adenoma 30.1 PRKAR1A POMC MEN1
44 pituitary hormone deficiency, combined, 2 30.1 TRH PRL POU1F1 POMC IGF1 GH1
45 fibrous dysplasia 30.1 SST PRL IGF1 GH1
46 pseudohypoparathyroidism 30.1 TRH PRL PRKAR1A IGF1
47 sleep disorder 30.1 PRL POMC IGF1
48 pheochromocytoma 30.1 SSTR1 SST PRL POMC MEN1 IGF1
49 thyroid gland disease 30.0 TRH SST PRL POMC IGF1
50 glucose intolerance 30.0 SST PRL POMC IGF1 GH1

Graphical network of the top 20 diseases related to Pituitary Adenoma, Prolactin-Secreting:



Diseases related to Pituitary Adenoma, Prolactin-Secreting

Symptoms & Phenotypes for Pituitary Adenoma, Prolactin-Secreting

Human phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

58 31 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 impotence 58 31 hallmark (90%) Very frequent (99-80%) HP:0000802
2 galactorrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0100829
3 decreased fertility in males 58 31 hallmark (90%) Very frequent (99-80%) HP:0012041
4 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
5 irregular menstruation 58 31 hallmark (90%) Very frequent (99-80%) HP:0000858
6 amenorrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0000141
7 decreased fertility in females 58 31 hallmark (90%) Very frequent (99-80%) HP:0000868
8 female hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000134
9 decreased female libido 58 31 hallmark (90%) Very frequent (99-80%) HP:0030018
10 hypogonadotropic hypogonadism 31 hallmark (90%) HP:0000044
11 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
12 osteopenia 58 31 frequent (33%) Frequent (79-30%) HP:0000938
13 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
14 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
15 progressive visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000529
16 osteoporosis 58 31 frequent (33%) Frequent (79-30%) HP:0000939
17 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
18 easy fatigability 58 31 frequent (33%) Frequent (79-30%) HP:0003388
19 gynecomastia 58 31 frequent (33%) Frequent (79-30%) HP:0000771
20 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
21 dyspareunia 58 31 frequent (33%) Frequent (79-30%) HP:0030016
22 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
23 adrenocorticotropic hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011748
24 decreased circulating acth level 58 31 frequent (33%) Frequent (79-30%) HP:0002920
25 secondary growth hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008240
26 adrenocorticotropin deficient adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011735
27 abnormal hair quantity 31 frequent (33%) HP:0011362
28 ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000508
29 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
30 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
31 delayed puberty 58 31 occasional (7.5%) Occasional (29-5%) HP:0000823
32 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
33 growth hormone excess 58 31 occasional (7.5%) Occasional (29-5%) HP:0000845
34 oculomotor nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012246
35 sudden loss of visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001117
36 cranial nerve vi palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0006897
37 fourth cranial nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0007011
38 internal ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007942
39 bitemporal hemianopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0030521
40 seizure 31 occasional (7.5%) HP:0001250
41 seizures 58 Occasional (29-5%)
42 nausea and vomiting 58 Frequent (79-30%)
43 cranial nerve paralysis 58 Occasional (29-5%)
44 hypogonadotrophic hypogonadism 58 Very frequent (99-80%)
45 anterior hypopituitarism 58 Occasional (29-5%)
46 abnormality of the menstrual cycle 58 Very frequent (99-80%)
47 erectile dysfunction 58 Very frequent (99-80%)
48 pituitary prolactin cell adenoma 31 HP:0006767
49 hypogonadism 58 Very frequent (99-80%)
50 hemianopia 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Oncology:
prolactinoma
prolactin-secreting pituitary adenoma

Clinical features from OMIM®:

600634 (Updated 20-May-2021)

GenomeRNAi Phenotypes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.7 MEN1
2 Decreased viability GR00221-A-1 9.7 PRKAR1A
3 Decreased viability GR00221-A-2 9.7 PRKAR1A
4 Decreased viability GR00221-A-3 9.7 PRKAR1A
5 Decreased viability GR00221-A-4 9.7 PRKAR1A
6 Decreased viability GR00240-S-1 9.7 AIP CORT SST
7 Decreased viability GR00249-S 9.7 GH1 SSTR2 SSTR4 SSTR5
8 Decreased viability GR00381-A-1 9.7 CORT SSTR3 SSTR5
9 Decreased viability GR00381-A-2 9.7 CORT
10 Decreased viability GR00381-A-3 9.7 CORT
11 Decreased viability GR00386-A-1 9.7 CORT LRP2 POMC TRH
12 Decreased viability GR00402-S-2 9.7 CORT SSTR3 SSTR5

MGI Mouse Phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 CDH23 CORT DRD2 LRP2 POMC PRKAR1A
2 homeostasis/metabolism MP:0005376 10.36 AIP CDH23 CORT DRD2 IGF1 LRP2
3 growth/size/body region MP:0005378 10.28 AIP CDH23 CORT DRD2 IGF1 LRP2
4 endocrine/exocrine gland MP:0005379 10.27 AIP CORT DRD2 IGF1 LRP2 MEN1
5 cellular MP:0005384 10.24 AIP CDH23 DRD2 IGF1 LRP2 MEN1
6 immune system MP:0005387 10.15 CDH23 DRD2 IGF1 LRP2 MEN1 POMC
7 digestive/alimentary MP:0005381 10.08 CDH23 DRD2 LRP2 MEN1 PRKAR1A SST
8 adipose tissue MP:0005375 10.07 CDH23 DRD2 IGF1 POMC PRKAR1A PTTG1
9 nervous system MP:0003631 10.07 CDH23 DRD2 IGF1 LRP2 MEN1 POMC
10 neoplasm MP:0002006 9.87 AIP DRD2 IGF1 MEN1 POMC PRKAR1A
11 no phenotypic analysis MP:0003012 9.76 DRD2 LRP2 POMC PTTG1 SST SSTR3
12 pigmentation MP:0001186 9.35 DRD2 LRP2 POMC POU1F1 PRKAR1A
13 reproductive system MP:0005389 9.32 CDH23 DRD2 IGF1 LRP2 MEN1 POU1F1

Drugs & Therapeutics for Pituitary Adenoma, Prolactin-Secreting

Drugs for Pituitary Adenoma, Prolactin-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
2
Cabergoline Approved Phase 4 81409-90-7 54746
3
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
4 Cardiotonic Agents Phase 4
5 Protective Agents Phase 4
6 Sympathomimetics Phase 4
7
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
8
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
9
Sodium citrate Approved, Investigational Phase 2 68-04-2
10
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
11
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
12
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
14
Enclomiphene Investigational Phase 2 15690-57-0
15 Estrogen Antagonists Phase 2
16 Citrate Phase 2
17 Estrogen Receptor Antagonists Phase 2
18 Clomiphene Phase 2
19 Estrogens Phase 2
20 Zuclomiphene Phase 2
21 Estrogen Receptor Modulators Phase 2
22 Protein Kinase Inhibitors Phase 2
23 Dopamine agonists Phase 1, Phase 2
24 Dopamine Agents Phase 1, Phase 2
25 Neurotransmitter Agents Phase 1, Phase 2
26 Antiparkinson Agents Phase 1, Phase 2
27
Curcumin Approved, Experimental, Investigational Phase 1 458-37-7 969516
28
Turmeric Approved, Experimental, Investigational Phase 1
29
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
31 Antirheumatic Agents Phase 1
32 Turmeric extract Phase 1
33 Anti-Inflammatory Agents, Non-Steroidal Phase 1
34 Analgesics Phase 1
35 Analgesics, Non-Narcotic Phase 1
36 Hormones Phase 1
37 Hormone Antagonists Phase 1
38 Anti-Inflammatory Agents Phase 1
39 Gastrointestinal Agents Phase 1
40 Antiemetics Phase 1
41 glucocorticoids Phase 1
42 Antineoplastic Agents, Hormonal Phase 1
43 BB 1101 Phase 1
44
Hydroxychloroquine Approved 118-42-3 3652
45
chloroquine Approved, Investigational, Vet_approved 54-05-7 2719
46
Metronidazole Approved 443-48-1 4173
47 Chloroquine diphosphate 50-63-5
48 insulin
49 Insulin, Globin Zinc
50 Arginine Vasopressin

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
2 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
4 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
5 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability Active, not recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
6 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
7 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
8 PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France) Unknown status NCT02854228
9 The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas Unknown status NCT03400865 HCQ/CQ and CAB combined treatment
10 Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Unknown status NCT02536261
11 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Cabergoline;cabergoline
12 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
13 Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists Completed NCT00481299
14 Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline Completed NCT00460616 Cabergoline
15 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
16 Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma Recruiting NCT03353025 dopamine agonist treatment
17 Validation of a Novel Patient-Reported Quality of Life Metric "Prolac-10" for Patients Undergoing Medical Therapy for Prolactinoma Recruiting NCT04106531
18 Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial Recruiting NCT03457389 Cabergoline
19 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
20 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595
21 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
22 The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. Not yet recruiting NCT03717454 Drug treatment

Search NIH Clinical Center for Pituitary Adenoma, Prolactin-Secreting

Cochrane evidence based reviews: prolactinoma

Genetic Tests for Pituitary Adenoma, Prolactin-Secreting

Genetic tests related to Pituitary Adenoma, Prolactin-Secreting:

# Genetic test Affiliating Genes
1 Prolactin-Producing Pituitary Gland Adenoma 29

Anatomical Context for Pituitary Adenoma, Prolactin-Secreting

MalaCards organs/tissues related to Pituitary Adenoma, Prolactin-Secreting:

40
Pituitary, Thyroid, Bone, Breast, Liver, Heart, Brain

Publications for Pituitary Adenoma, Prolactin-Secreting

Articles related to Pituitary Adenoma, Prolactin-Secreting:

(show top 50) (show all 2242)
# Title Authors PMID Year
1
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. 57 54
17244780 2007
2
Clinical practice. Prolactinoma. 57 61
14627789 2003
3
Familial prolactinoma. 61 57
7621566 1995
4
Pituitary adenoma predisposition caused by germline mutations in the AIP gene. 57
16728643 2006
5
Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. 61 54
20130078 2010
6
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. 61 54
19890024 2010
7
Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. 61 54
20205839 2010
8
The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. 54 61
19905999 2009
9
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. 61 54
19509108 2009
10
An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein. 61 54
19391077 2009
11
Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism. 61 54
19675520 2009
12
Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. 54 61
18791324 2009
13
Endocrine actions of cortistatin: in vivo studies. 61 54
18281148 2008
14
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. 61 54
18426817 2008
15
Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence? 61 54
17638022 2008
16
Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. 61 54
17540335 2007
17
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. 61 54
17287403 2007
18
Giant prolactinomas in adolescence: an uncommon cause of blindness. 61 54
16983572 2007
19
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. 54 61
17222350 2007
20
[IGF-1 plasma levels evaluation in prolactinoma]. 61 54
17057896 2006
21
Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. 61 54
16886952 2006
22
Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. 54 61
16598425 2006
23
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. 61 54
16449338 2006
24
Genesis of prolactinomas: studies using estrogen-treated animals. 61 54
16809921 2006
25
Bone morphogenetic protein-4 control of pituitary pathophysiology. 61 54
16809920 2006
26
A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy. 54 61
16421054 2005
27
Treatment of pituitary tumors: dopamine agonists. 61 54
16311416 2005
28
Hypercalcemia and local production of parathyroid hormone-related protein by a perisellar rhabdomyosarcoma after remote pituitary irradiation. 61 54
16239205 2005
29
Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. 61 54
16411064 2005
30
[The best approach to treat prolactinoma]. 61 54
15559242 2004
31
Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen. 61 54
15221415 2004
32
Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. 54 61
15181056 2004
33
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. 61 54
15070915 2004
34
Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. 54 61
14525955 2004
35
Somatostatin receptors in pituitary function, diagnosis and therapy. 61 54
15281350 2004
36
Diagnosis and management of pituitary tumors: recent advances. 61 54
15024895 2003
37
Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. 54 61
12972179 2003
38
Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas. 61 54
14599121 2003
39
Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. 61 54
12794059 2003
40
Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. 54 61
12554778 2003
41
Macroprolactinaemia associated with prolactin adenoma. 54 61
12660284 2003
42
[The role of somatostatin analogues in the treatment of hypophyseal adenomas]. 61 54
12621362 2003
43
Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia. 61 54
12735420 2003
44
Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. 54 61
12574225 2003
45
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. 54 61
12552124 2003
46
[New mechanisms involved in the pathogenesis of pituitary adenomas]. 61 54
12793085 2003
47
Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. 61 54
12481018 2002
48
The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. 54 61
12459032 2002
49
"Hook effect" in prolactinomas: case report and review of literature. 61 54
12173917 2002
50
The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. 61 54
11956103 2002

Variations for Pituitary Adenoma, Prolactin-Secreting

ClinVar genetic disease variations for Pituitary Adenoma, Prolactin-Secreting:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LRP2 NM_004525.3(LRP2):c.13753C>T (p.Arg4585Ter) SNV Likely pathogenic 374076 rs202057289 GRCh37: 2:169985570-169985570
GRCh38: 2:169129060-169129060

Cosmic variations for Pituitary Adenoma, Prolactin-Secreting:

9 (show top 50) (show all 59)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87132301 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 27
2 COSM148932717 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 27
3 COSM148932735 PIK3CA pituitary,NS,adenoma,PRL c.*153A>G p.? 3:179234230-179234230 27
4 COSM87132318 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 27
5 COSM101951679 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
6 COSM101967337 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
7 COSM105721467 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
8 COSM91331236 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 27
9 COSM112988978 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
10 COSM112988917 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 27
11 COSM105721542 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
12 COSM101951743 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
13 COSM91331304 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
14 COSM101967380 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
15 COSM93760866 GNAS pituitary,NS,adenoma,GH c.2530C>T p.R844C 20:58909365-58909365 27
16 COSM93630265 GNAS pituitary,NS,adenoma,GH-alpha SU c.*507C>T p.? 20:58909365-58909365 27
17 COSM87642925 GNAS pituitary,NS,adenoma,GH c.94-402C>T p.? 20:58909365-58909365 27
18 COSM93086636 GNAS pituitary,NS,adenoma,GH c.604C>T p.R202C 20:58909365-58909365 27
19 COSM93726285 GNAS pituitary,NS,adenoma,GH c.559C>T p.R187C 20:58909365-58909365 27
20 COSM93726301 GNAS pituitary,NS,adenoma,GH c.560G>A p.R187H 20:58909366-58909366 27
21 COSM85346237 GNAS pituitary,NS,adenoma,GH c.635A>T p.Q212L 20:58909541-58909541 27
22 COSM85345830 GNAS pituitary,NS,adenoma,GH c.556C>T p.R186C 20:58909365-58909365 27
23 COSM93779606 GNAS pituitary,NS,adenoma,GH c.2488C>T p.R830C 20:58909365-58909365 27
24 COSM89474843 GNAS pituitary,NS,adenoma,GH c.*504C>T p.? 20:58909365-58909365 27
25 COSM93702294 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 27
26 COSM93701960 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 27
27 COSM85345852 GNAS pituitary,NS,adenoma,GH c.557G>A p.R186H 20:58909366-58909366 27
28 COSM87642939 GNAS pituitary,NS,adenoma,GH c.94-401G>A p.? 20:58909366-58909366 27
29 COSM93726636 GNAS pituitary,NS,adenoma,GH c.638A>T p.Q213L 20:58909541-58909541 27
30 COSM93726530 GNAS pituitary,NS,adenoma,GH c.559C>A p.R187S 20:58909365-58909365 27
31 COSM93086945 GNAS pituitary,NS,adenoma,GH c.683A>T p.Q228L 20:58909541-58909541 27
32 COSM93779631 GNAS pituitary,NS,adenoma,GH c.2489G>A p.R830H 20:58909366-58909366 27
33 COSM93779988 GNAS pituitary,NS,adenoma,GH c.2567A>T p.Q856L 20:58909541-58909541 27
34 COSM93780281 GNAS pituitary,NS,adenoma,GH c.2567A>G p.Q856R 20:58909541-58909541 27
35 COSM93761460 GNAS pituitary,NS,adenoma,GH c.2609A>T p.Q870L 20:58909541-58909541 27
36 COSM93630681 GNAS pituitary,NS,adenoma,GH c.*586A>T p.? 20:58909541-58909541 27
37 COSM87643126 GNAS pituitary,NS,adenoma,GH c.94-402C>A p.? 20:58909365-58909365 27
38 COSM93702186 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 27
39 COSM93086649 GNAS pituitary,NS,adenoma,GH c.605G>A p.R202H 20:58909366-58909366 27
40 COSM93761837 GNAS pituitary,NS,adenoma,GH c.2609A>G p.Q870R 20:58909541-58909541 27
41 COSM85346567 GNAS pituitary,NS,adenoma,GH c.635A>G p.Q212R 20:58909541-58909541 27
42 COSM93760887 GNAS pituitary,NS,adenoma,GH c.2531G>A p.R844H 20:58909366-58909366 27
43 COSM93701978 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 27
44 COSM89475152 GNAS pituitary,NS,adenoma,GH c.*504C>A p.? 20:58909365-58909365 27
45 COSM93726964 GNAS pituitary,NS,adenoma,GH c.638A>G p.Q213R 20:58909541-58909541 27
46 COSM89474878 GNAS pituitary,NS,adenoma,GH c.*505G>A p.? 20:58909366-58909366 27
47 COSM87643479 GNAS pituitary,NS,adenoma,GH c.94-226A>G p.? 20:58909541-58909541 27
48 COSM87643227 GNAS pituitary,NS,adenoma,GH c.94-226A>T p.? 20:58909541-58909541 27
49 COSM93086861 GNAS pituitary,NS,adenoma,GH c.604C>A p.R202S 20:58909365-58909365 27
50 COSM93631069 GNAS pituitary,NS,adenoma,GH c.*586A>G p.? 20:58909541-58909541 27

Expression for Pituitary Adenoma, Prolactin-Secreting

Search GEO for disease gene expression data for Pituitary Adenoma, Prolactin-Secreting.

Pathways for Pituitary Adenoma, Prolactin-Secreting

GO Terms for Pituitary Adenoma, Prolactin-Secreting

Cellular components related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.35 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2 endosome lumen GO:0031904 8.8 PRL LRP2 GH1

Biological processes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.17 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2 G protein-coupled receptor signaling pathway GO:0007186 10.1 TRH SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
3 cell-cell signaling GO:0007267 9.85 TRH SSTR3 SST POMC
4 negative regulation of cell proliferation GO:0008285 9.81 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
5 neuropeptide signaling pathway GO:0007218 9.73 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 POMC
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.72 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
7 cerebellum development GO:0021549 9.69 SSTR3 SSTR2 SSTR1
8 cellular response to glucocorticoid stimulus GO:0071385 9.67 SSTR5 SSTR4 SSTR3 SSTR2
9 response to starvation GO:0042594 9.65 SSTR3 SSTR2 SSTR1
10 cellular response to estradiol stimulus GO:0071392 9.63 SSTR3 SSTR2 SSTR1
11 regulation of protein kinase A signaling GO:0010738 9.58 PRKAR1A AIP
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.57 PRL GH1
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.56 IGF1 GH1
14 peristalsis GO:0030432 9.54 SSTR2 DRD2
15 adenohypophysis development GO:0021984 9.52 POU1F1 DRD2
16 hormone-mediated apoptotic signaling pathway GO:0008628 9.49 SSTR3 SST
17 forebrain development GO:0030900 9.43 SSTR4 SSTR3 SSTR2 SSTR1 LRP2 DRD2
18 somatostatin signaling pathway GO:0038170 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Molecular functions related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 DRD2
2 peptide binding GO:0042277 9.65 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
3 neuropeptide binding GO:0042923 9.55 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
4 hormone activity GO:0005179 9.5 TRH SST PRL POMC IGF1 GH1
5 prolactin receptor binding GO:0005148 9.32 PRL GH1
6 somatostatin receptor activity GO:0004994 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Sources for Pituitary Adenoma, Prolactin-Secreting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....